Search research articles
Contact Us
Filters
Showing results (1-10 of 30) with videos related to
Page
of 3
Sort By:
Expert Review of Clinical Pharmacology
|
January 14, 2014
Design and analysis considerations for thorough QT studies employing conventional (10 s, 12-lead) ECG recordings
Charles M Beasley, Alex Dmitrienko, Malcolm I Mitchell
Journal of Psychopharmacology (Oxford, England)
|
June 19, 2010
Weight changes over time in adults treated with the oral or depot formulations of olanzapine: a pooled analysis of 86 clinical trials
Brian A Millen, Giedra M Campbell, Charles M Beasley
International Clinical Psychopharmacology
|
December 20, 2002
Extrapyramidal symptom profiles assessed with the Drug-Induced Extrapyramidal Symptom Scale: comparison with Western scales in the clinical double-blind studies of schizophrenic patients treated with either olanzapine or haloperidol
Toshiya Inada, Charles M Beasley, Yoko Tanaka, et al.
Psychiatry Research
|
July 16, 2003
Effects of intramuscular olanzapine vs. haloperidol and placebo on QTc intervals in acutely agitated patients
Stacy R Lindborg, Charles M Beasley, Karla Alaka, et al.
Psychological Medicine
|
July 21, 2007
Evaluating suicide-related adverse events in clinical trials of fluoxetine treatment in adults for indications other than major depressive disorder
Sitra Tauscher-Wisniewski, Damon Disch, John Plewes, et al.
Journal of Clinical Psychopharmacology
|
January 18, 2006
Is quality of life among minimally symptomatic patients with schizophrenia better following withdrawal or continuation of antipsychotic treatment?
Charles M Beasley, Virginia K Sutton, Cindy C Taylor, et al.
Psychopharmacology Bulletin
|
June 29, 2010
Early predictors of weight gain risk during treatment with olanzapine: analysis of pooled data from 58 clinical trials
Ilya Lipkovich, Jennie G Jacobson, Cathy Caldwell, et al.
Journal of Clinical Psychopharmacology
|
February 2, 2019
Twenty-Four-Hour Measures of Heart Rate-Corrected QT Interval, Peak-to-End of the T-Wave, and Peak-to-End of the T-Wave/Corrected QT Interval Ratio During Antipsychotic Treatment
Mevhibe N Tümüklü, Mustafa M Tümüklü, Vladislav Nesterenko, et al.
The Journal of Clinical Psychiatry
|
August 21, 2003
An integrated analysis of acute treatment-emergent extrapyramidal syndrome in patients with schizophrenia during olanzapine clinical trials: comparisons with placebo, haloperidol, risperidone, or clozapine
Christopher D Carlson, Patrizia A Cavazzoni, Paul H Berg, et al.
The Journal of Sexual Medicine
|
January 21, 2006
Efficacy and safety of oral tadalafil in the treatment of men in Canada with erectile dysfunction: a randomized, double-blind, parallel, placebo-controlled clinical trial
Serge Carrier, Gerald B Brock, Peter J Pommerville, et al.
Page
of 3
Search research articles
Search
Showing results (1-10 of 30) with videos related to
Sort By:
Page
of 3
Expert Review of Clinical Pharmacology
|
January 14, 2014
Design and analysis considerations for thorough QT studies employing conventional (10 s, 12-lead) ECG recordings
Charles M Beasley, Alex Dmitrienko, Malcolm I Mitchell
Journal of Psychopharmacology (Oxford, England)
|
June 19, 2010
Weight changes over time in adults treated with the oral or depot formulations of olanzapine: a pooled analysis of 86 clinical trials
Brian A Millen, Giedra M Campbell, Charles M Beasley
International Clinical Psychopharmacology
|
December 20, 2002
Extrapyramidal symptom profiles assessed with the Drug-Induced Extrapyramidal Symptom Scale: comparison with Western scales in the clinical double-blind studies of schizophrenic patients treated with either olanzapine or haloperidol
Toshiya Inada, Charles M Beasley, Yoko Tanaka, et al.
Psychiatry Research
|
July 16, 2003
Effects of intramuscular olanzapine vs. haloperidol and placebo on QTc intervals in acutely agitated patients
Stacy R Lindborg, Charles M Beasley, Karla Alaka, et al.
Psychological Medicine
|
July 21, 2007
Evaluating suicide-related adverse events in clinical trials of fluoxetine treatment in adults for indications other than major depressive disorder
Sitra Tauscher-Wisniewski, Damon Disch, John Plewes, et al.
Journal of Clinical Psychopharmacology
|
January 18, 2006
Is quality of life among minimally symptomatic patients with schizophrenia better following withdrawal or continuation of antipsychotic treatment?
Charles M Beasley, Virginia K Sutton, Cindy C Taylor, et al.
Psychopharmacology Bulletin
|
June 29, 2010
Early predictors of weight gain risk during treatment with olanzapine: analysis of pooled data from 58 clinical trials
Ilya Lipkovich, Jennie G Jacobson, Cathy Caldwell, et al.
Journal of Clinical Psychopharmacology
|
February 2, 2019
Twenty-Four-Hour Measures of Heart Rate-Corrected QT Interval, Peak-to-End of the T-Wave, and Peak-to-End of the T-Wave/Corrected QT Interval Ratio During Antipsychotic Treatment
Mevhibe N Tümüklü, Mustafa M Tümüklü, Vladislav Nesterenko, et al.
The Journal of Clinical Psychiatry
|
August 21, 2003
An integrated analysis of acute treatment-emergent extrapyramidal syndrome in patients with schizophrenia during olanzapine clinical trials: comparisons with placebo, haloperidol, risperidone, or clozapine
Christopher D Carlson, Patrizia A Cavazzoni, Paul H Berg, et al.
The Journal of Sexual Medicine
|
January 21, 2006
Efficacy and safety of oral tadalafil in the treatment of men in Canada with erectile dysfunction: a randomized, double-blind, parallel, placebo-controlled clinical trial
Serge Carrier, Gerald B Brock, Peter J Pommerville, et al.
Page
of 3